SOUTH SAN FRANCISCO, Calif.,
Dec. 17, 2019 /PRNewswire/
-- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA)
today announced its support of the American Heart
Association®/American Stroke Association's®
newest initiative for enhanced awareness and understanding of best
care practices for hemorrhagic stroke, or severe bleeding in the
brain.
Intracerebral hemorrhage (ICH), or hemorrhagic strokes, make up
about 10 percent of the 795,000 stroke cases per year. On average,
someone in the United States has a
stroke every 40 seconds. A hemorrhagic stroke occurs when a
weakened blood vessel ruptures and spills blood into the brain.
When a stroke occurs, immediate treatment may minimize the
long-term effects of a stroke and even prevent death.
"We're proud to support the American Heart Association's
education efforts around best practices for treating this
life-threatening condition," said Scott
Garland, Portola's
president and chief executive officer. "We believe in the potential
of the new best practices initiative from the Association to make a
significant impact on the national awareness of hemorrhagic
stroke—a critical component in helping to empower healthcare
providers to deliver the highest level of quality patient care
possible."
Stroke costs the United States
an estimated $45.5 billion each year,
including direct and indirect costs such as health care services,
medicines to treat stroke and missed days of work, according to the
American Heart Association.
"We're pleased to announce this new initiative with support from
Portola, which builds on our Get
With The Guidelines® hospital-based quality improvement
program," said John Meiners, chief
of mission aligned businesses and healthcare solutions for the
American Heart Association. "The combined efforts will allow us to
further provide hemorrhagic stroke education in the hopes that it
will help physicians in saving patient lives and hastening
recovery."
Get With The Guidelines® (GWTG) is a hospital-based
quality improvement program from the American Heart Association
with tools and resources to increase adherence to the latest
research-based guidelines. The premise of the GWTG programs is when
medical professionals apply the most up-to-date evidence-based
treatment guidelines, patient outcomes are improved.
More information about this initiative will be announced at the
American Heart Association/American Stroke Association's annual
International Stroke Conference, February
18-21, 2020.
About Portola Pharmaceuticals, Inc.
Portola
Pharmaceuticals is a global, commercial-stage biopharmaceutical
company focused on the discovery, development and commercialization
of novel therapeutics that could significantly advance the fields
of thrombosis and other hematologic conditions. The Company's first
two commercialized products are
Andexxa® [coagulation factor Xa (recombinant),
inactivated-zhzo], marketed in Europe as
Ondexxya® (andexanet alfa), and
Bevyxxa® (betrixaban). The company also is
advancing cerdulatinib, a SYK/JAK inhibitor being developed for the
treatment of hematologic cancers. Founded in 2003 in South San
Francisco, California, Portola has operations in the
United States and Europe.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/portola-pharmaceuticals-to-support-new-american-heart-association-initiative-to-address-hemorrhagic-stroke-300975571.html
SOURCE Portola Pharmaceuticals, Inc.®